article thumbnail

Why VCs fell in love with pharma R&D in 2021

pharmaphorum

That culture clash makes it hard to innovate the world of pharma at scale and with any rapidity. And investment in pharma followed suit: pharma companies were looked at as stable assets — reliable but unlikely to balloon in value like a tech company might. Start-ups move fast and break things.